Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmoset

Cytokine and Growth Factor Concentration in Cerebrospinal Fluid from Patients with Hydrocephalus Following Endovascular Embolization of Unruptured Aneurysms in Comparison with Other Types of Hydrocephalus

“…Although the induction of hydrocephalus is possible in experimental models from the overexpression of TGF-b1 [31,32] and FGF-2 [33,34], the lack of growth factor expression in the CSF of the molecules in the hemorrhage, unruptured aneurysm, and normal pressure hydrocephalus groups implies that growth factors are not involved in the pathogenesis of hydrocephalus in these patient populations. From these and previous results [16,20], the correlation between inflammation, SAH, and hydrocephalus is clear.…”

Angiogenic Factors in the Central Nervous System

“…Gene transfer of VEGF or SF/HGF to the subarachnoid space of rats induces cortical angiogenesis and improves blood flow during cerebral hypoperfusion in a rat model (321). Potential disadvantages of the use of bFGF to promote cerebral angiogenesis include hydrocephalus (206), and VEGF administration in the brain carries the risk of promoting cerebral edema. An alternative approach may be to use other angiogenic factors, such as Ang-1, alone or in combination with VEGF.…”

Neuroprotective compounds and innovative therapeutic strategies for Parkinson’s disease: experimental and clinical studies

“…Experimental data Initial studies tested the effect of the direct, intra-cerebral infusion of numerous factors, including epidermal growth factor, basic fibroblast growth factor, BDNF, neurturin (NTN), and GDNF, [113][114][115][116][117][118][119][120][121] which showed variable degrees of neuroprotection. GDNF repeatedly proved the most potent and consistent agent in counteracting the effects of the neurotoxins used to reproduce PD-like pathology.…”